WO2011044230A9 - N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions - Google Patents
N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions Download PDFInfo
- Publication number
- WO2011044230A9 WO2011044230A9 PCT/US2010/051623 US2010051623W WO2011044230A9 WO 2011044230 A9 WO2011044230 A9 WO 2011044230A9 US 2010051623 W US2010051623 W US 2010051623W WO 2011044230 A9 WO2011044230 A9 WO 2011044230A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amide
- diseases
- treatment
- conditions
- acetylcysteine
- Prior art date
Links
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24912209P | 2009-10-06 | 2009-10-06 | |
US61/249,122 | 2009-10-06 | ||
US25180209P | 2009-10-15 | 2009-10-15 | |
US61/251,802 | 2009-10-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011044230A2 WO2011044230A2 (fr) | 2011-04-14 |
WO2011044230A9 true WO2011044230A9 (fr) | 2011-08-18 |
Family
ID=43857367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/051623 WO2011044230A2 (fr) | 2009-10-06 | 2010-10-06 | N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011044230A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10201513B2 (en) | 2016-12-19 | 2019-02-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US10660870B2 (en) | 2017-08-14 | 2020-05-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2854798A4 (fr) | 2012-05-24 | 2016-05-11 | Mograbi Josef | Compositions comprenant de l'isosilybine b pour l'amélioration et la prévention de la toxicité induite par un médicament |
CN103070294A (zh) * | 2013-01-31 | 2013-05-01 | 武汉工业学院 | N-乙酰半胱氨酰胺作为饲料添加剂的应用 |
WO2015006569A2 (fr) * | 2013-07-10 | 2015-01-15 | Sentient Lifesciences, Inc. | Emploi de n-acétylcystéine amide dans le traitement de lésions profondes à la tête |
WO2015112724A1 (fr) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Amide nac pour le traitement de dysfonctionnement cognitif aigu ou chronique |
WO2015112715A1 (fr) * | 2014-01-24 | 2015-07-30 | Brighton Biotech, Inc. | Naca pour le traitement d'un traumatisme cérébral à faible impact ou chronique |
EP3302456A4 (fr) * | 2015-06-05 | 2018-12-19 | Glenn A. Goldstein | Utilisation de n-acétylcystéine amide dans le traitement d'une surdose d'acétaminophène |
US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
US11766413B2 (en) * | 2019-01-11 | 2023-09-26 | Nacuity Pharmaceuticals, Inc. | Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R′)-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) |
US20220105056A1 (en) * | 2019-01-11 | 2022-04-07 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Dermatitis and Skin Lightening, Skin Whitening and Skin Improvement |
US20220062203A1 (en) * | 2019-01-11 | 2022-03-03 | Nacuity Pharmaceuticals, Inc. | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Pneumonitis and Treatment of Pulmonary Function in Cystic Fibrosis |
IL297531A (en) | 2020-04-24 | 2022-12-01 | Ashvattha Therapeutics Inc | Dendrimer preparations and methods for treating severe acute respiratory distress syndrome |
AU2021262136A1 (en) * | 2020-05-01 | 2022-12-08 | MUCPharm Pty Ltd | Preventing and treating viral infections |
US11911178B2 (en) | 2020-05-05 | 2024-02-27 | Northwestern University | System and method to detect and treat arrhythmogenic regions in atrial fibrillation |
NL2025679B1 (en) * | 2020-05-26 | 2021-12-13 | Johanna Daams Brechtje | Electrical stimulation for preventing or treating nitric oxide deficiency related conditions |
-
2010
- 2010-10-06 WO PCT/US2010/051623 patent/WO2011044230A2/fr active Application Filing
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10201513B2 (en) | 2016-12-19 | 2019-02-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10238617B2 (en) | 2016-12-19 | 2019-03-26 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10471034B2 (en) | 2016-12-19 | 2019-11-12 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US11129804B2 (en) | 2016-12-19 | 2021-09-28 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US11602511B2 (en) | 2016-12-19 | 2023-03-14 | Axcella Health Inc. | Amino acid compositions and methods for the treatment of liver diseases |
US10660870B2 (en) | 2017-08-14 | 2020-05-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US11571404B2 (en) | 2017-08-14 | 2023-02-07 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
US10596136B2 (en) | 2018-06-20 | 2020-03-24 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US10973793B2 (en) | 2018-06-20 | 2021-04-13 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US11833127B2 (en) | 2018-06-20 | 2023-12-05 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
Also Published As
Publication number | Publication date |
---|---|
WO2011044230A2 (fr) | 2011-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011044230A9 (fr) | N-acétylcystéine amide (nac amide) destiné au traitement de maladies et de conditions | |
IL186684A0 (en) | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress | |
AP3069A (en) | Thienopyridine derivatives for the treatment and prvention of dengue virus infection | |
EP2456757A4 (fr) | Inhibiteurs de hdac et procédés thérapeutiques les utilisant | |
IL193473A0 (en) | Amide derivatives and their application for the treatment of g protein related diseases | |
EP2182983A4 (fr) | Traitement de maladies amyloïdogéniques | |
SI2440550T1 (sl) | Indolamidni derivati in povezane spojine za uporabo pri zdravljenju neurodegenerativnih bolezni | |
HRP20141057T1 (en) | Novel compound useful for the treatment of degenerative and inflammatory diseases | |
IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
IL213703A (en) | Compounds for the treatment of pain and other diseases | |
EP2225196A4 (fr) | Inhibiteurs de cystéine-protéases pour le traitement de maladies parasitaires | |
GB0914423D0 (en) | Treatment of protein aggregation diseases | |
EP2488507A4 (fr) | Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies | |
IL213128A0 (en) | Processes for the preparation and purification of gabapentin enacarbil | |
EP2454229A4 (fr) | Dérivés d'acide aminé pour le traitement de la douleur neuropathique | |
IL223219A0 (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies | |
ZA201005770B (en) | The treatment of damaged skin | |
AU2009900848A0 (en) | Positive Inotrope Agent, Positive Lusitrope Agent and Agent for the Treatment of Related Diseases | |
AU2009900265A0 (en) | Treatment of diabetes and other diseases | |
GB0801511D0 (en) | The treatment of ophthalmic diseases | |
GB0901727D0 (en) | The treatment of ophthalmic diseases | |
AU2007902616A0 (en) | Treatment and prevention of influenza | |
GB0700755D0 (en) | The Treatment of ophthalmic diseases | |
AU2008901947A0 (en) | Treatment of Ores | |
AU2010903595A0 (en) | Treatment and diagnosis of epigenetic disorders and conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10822598 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10822598 Country of ref document: EP Kind code of ref document: A2 |